Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Cesar, Montaño Mejía"'
Autor:
Carmen Escuriola Ettingshausen, Vladimír Vdovin, Nadezhda Zozulya, Pavel Svirin, Tatiana Andreeva, Majda Benedik-Dolničar, Victor Jiménez-Yuste, Lidija Kitanovski, Silva Zupancic-Šalek, Anna Pavlova, Angelika Bátorová, Cesar Montaño Mejía, Gulnara Abdilova, Sigurd Knaub, Martina Jansen, Shannely Lowndes, Larisa Belyanskaya, Olaf Walter, Johannes Oldenburg
Publikováno v:
TH Open, Vol 06, Iss 02, Pp e124-e134 (2022)
Background Immune tolerance induction (ITI) with repeated factor VIII (FVIII) administration is the only strategy proven to eradicate inhibitors. The observational ITI study is evaluating ITI with a range of FVIII products. Methods This subgroup anal
Externí odkaz:
https://doaj.org/article/a52b126df9af4fd18ab2a85705afdb71
Autor:
Michelle Sholzberg, Kate Khair, Hassan Yaish, George Rodgers, Maria Sol Cruz, Cesar Montaño Mejía, Zuzana Čermáková, Davide Matino, Jerome Teitel, Alpha Barrie, Sylvia Werner, Mario von Depka Prondzinski
Publikováno v:
TH Open, Vol 05, Iss 03, Pp e264-e272 (2021)
Background The efficacy and safety of wilate (human von Willebrand factor/coagulation factor VIII) in patients with von Willebrand disease (VWD) has been demonstrated in clinical trials. Here, we present real-world data on the use of wilate for the r
Externí odkaz:
https://doaj.org/article/a6965a2bcf1e417995c222d845d97b3d
Autor:
Sylvia Werner, Cesar Montaño Mejía, Hassan M. Yaish, George M. Rodgers, Kate Khair, Michelle Sholzberg, Jerome M. Teitel, Davide Matino, Zuzana Cermakova, Alpha Barrie, Mario von Depka Prondzinski, Maria Sol Cruz
Publikováno v:
TH Open, Vol 05, Iss 03, Pp e264-e272 (2021)
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open: Companion Journal to Thrombosis and Haemostasis
Background The efficacy and safety of wilate (human von Willebrand factor/coagulation factor VIII) in patients with von Willebrand disease (VWD) has been demonstrated in clinical trials. Here, we present real-world data on the use of wilate for the r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::016887afaa344c541c7fe8d7254aec51
https://doi.org/10.1055/s-0041-1730283
https://doi.org/10.1055/s-0041-1730283
Autor:
Carmen, Escuriola Ettingshausen, Vladimír, Vdovin, Nadezhda, Zozulya, Pavel, Svirin, Tatiana, Andreeva, Majda, Benedik-Dolničar, Victor, Jiménez-Yuste, Lidija, Kitanovski, Silva, Zupancic-Šalek, Anna, Pavlova, Angelika, Bátorová, Cesar, Montaño Mejía, Gulnara, Abdilova, Sigurd, Knaub, Martina, Jansen, Shannely, Lowndes, Larisa, Belyanskaya, Olaf, Walter, Johannes, Oldenburg
Publikováno v:
TH open : companion journal to thrombosis and haemostasis. 6(2)
Background Immune tolerance induction (ITI) with repeated factor VIII (FVIII) administration is the only strategy proven to eradicate inhibitors. The observational ITI study is evaluating ITI with a range of FVIII products. Methods This subgroup anal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa2e258334b174cbbd5a342542bc6f59
https://pubmed.ncbi.nlm.nih.gov/35707623
https://pubmed.ncbi.nlm.nih.gov/35707623